Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) passed below its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $117.58 and traded as low as $114.40. Kymera Therapeutics shares last traded at $115.10, with a volume of 1,278,323 shares trading hands.
Wall Street Analyst Weigh In
KYMR has been the subject of several recent research reports. Citigroup increased their price objective on Kymera Therapeutics from $135.00 to $150.00 and gave the stock a "buy" rating in a report on Monday, October 5th. Truist Financial restated a "buy" rating and set a $150.00 target price (up from $136.00) on shares of Kymera Therapeutics in a research note on Friday, October 30th. Morgan Stanley upped their target price on Kymera Therapeutics from $135.00 to $146.00 and gave the company an "overweight" rating in a research note on Tuesday, October 27th. Deutsche Bank initiated coverage on Kymera Therapeutics in a research note on Thursday, July 30th. They set a "hold" rating and a $120.00 price objective for the company. Finally, Bank of America upped their price target on shares of Kymera Therapeutics from $123.00 to $144.00 and gave the stock a "buy" rating in a research report on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $139.16.
Check Out Our Latest Analysis on Kymera Therapeutics
Kymera Therapeutics Stock Performance
The stock has a fifty day simple moving average of $117.58 and a 200-day simple moving average of $100.51. The stock has a market cap of $9.83 billion, a P/E ratio of -31.80 and a beta of 2.04.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.26) by ($0.06). The business had revenue of $1.35 million for the quarter, compared to analyst estimates of $3.28 million. Kymera Therapeutics had a negative return on equity of 22.39% and a negative net margin of 285.33%. The business's revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.94) EPS. On average, research analysts anticipate that Kymera Therapeutics, Inc. will post -3.88 earnings per share for the current year.
Insider Activity
In related news, CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $113.80, for a total value of $3,414,000.00. Following the completion of the transaction, the chief executive officer owned 666,568 shares of the company's stock, valued at $75,855,438.40. The trade was a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Brian Adams sold 6,371 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the sale, the insider owned 50,254 shares in the company, valued at $5,871,174.82. This represents a 11.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 15.98% of the company's stock.
Institutional Investors Weigh In On Kymera Therapeutics
Several hedge funds have recently modified their holdings of the company. Knights of Columbus Asset Advisors LLC boosted its position in Kymera Therapeutics by 0.5% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 18,396 shares of the company's stock valued at $2,056,000 after acquiring an additional 83 shares during the last quarter. GAMMA Investing LLC raised its position in Kymera Therapeutics by 27.5% in the 2nd quarter. GAMMA Investing LLC now owns 454 shares of the company's stock valued at $52,000 after buying an additional 98 shares during the last quarter. Abel Hall LLC lifted its position in shares of Kymera Therapeutics by 4.0% during the 3rd quarter. Abel Hall LLC now owns 4,870 shares of the company's stock worth $544,000 after buying an additional 189 shares in the last quarter. Proficio Capital Partners LLC boosted its holdings in shares of Kymera Therapeutics by 1.8% in the 2nd quarter. Proficio Capital Partners LLC now owns 11,045 shares of the company's stock worth $1,267,000 after buying an additional 200 shares during the last quarter. Finally, Glenmede Trust Co. NA lifted its stake in Kymera Therapeutics by 3.6% in the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company's stock valued at $565,000 after purchasing an additional 235 shares during the last quarter.
About Kymera Therapeutics
(
Get Free Report)
Kymera Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines that selectively remove disease-causing proteins from cells. Its approach, known as targeted protein degradation, uses the body's natural protein-disposal system and is designed to address targets that may be difficult to reach with conventional drugs. The company's research and development programs include small-molecule protein degraders for conditions involving immune and inflammatory pathways, as well as cancer.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.